Current Opinion in Immunology最新文献_第7页

Editorial overview: The march of mucosal vaccines 编辑综述：粘膜疫苗的发展。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-12-20 DOI: 10.1016/j.coi.2023.102408

EC Lavelle, Meritxell Genescà

引用次数: 0

Differential signaling by type-I and type-III interferons in mucosa I 型和 III 型干扰素在粘膜中的信号传导差异。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-12-20 DOI: 10.1016/j.coi.2023.102400

Megan L Stanifer, Steeve Boulant

{"title":"Differential signaling by type-I and type-III interferons in mucosa","authors":"Megan L Stanifer, Steeve Boulant","doi":"10.1016/j.coi.2023.102400","DOIUrl":"10.1016/j.coi.2023.102400","url":null,"abstract":"<div><p>Mucosal surfaces are barrier sites that protect the body from the outside environment. They have developed mechanisms to handle microbiota-associated triggers while remaining responsive to pathogens. Cells at mucosal surfaces rely on both the type-I and -III interferons (IFNs) as key cytokines to protect the epithelium itself and to prevent systemic spread of viral infections. Type-I and -III IFNs have been shown to use distinct receptors but similar JAK/STAT signaling cascades to elicit the induction of IFN-stimulated genes. These overlapping cascades led to the original hypothesis that both IFNs provided redundant functions at mucosal surfaces. However, accumulating evidence points toward a different model where each IFN provides a unique protective and homeostatic function as well as distinct antiviral protection to epithelial cells. This review will highlight recent work shedding light on the differences in how both type -I and -III IFNs induce receptor-mediated signaling to protect mucosal surfaces.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"86 ","pages":"Article 102400"},"PeriodicalIF":7.0,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S095279152300119X/pdfft?md5=d01f0ec7113e74871a97194b80898a32&pid=1-s2.0-S095279152300119X-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138833657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recent advances in enterotoxin vaccine adjuvants 肠毒素疫苗佐剂的最新进展

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-11-16 DOI: 10.1016/j.coi.2023.102398

Jessica W Crothers , Elizabeth B Norton

{"title":"Recent advances in enterotoxin vaccine adjuvants","authors":"Jessica W Crothers , Elizabeth B Norton","doi":"10.1016/j.coi.2023.102398","DOIUrl":"https://doi.org/10.1016/j.coi.2023.102398","url":null,"abstract":"<div><p>Enterotoxin adjuvants have been researched for their ability to promote immunity to co-delivered antigens. Outside of cholera vaccines, however, these proteins have yet to be included in any currently licensed vaccines. They include molecules derived from the bacterial toxins of <em>Vibrio cholerae</em>, cholera toxin, or <em>Escherichia coli</em>, heat-labile toxin, such as detoxified mutants or subunits. This class of adjuvants is distinguished by their delivery possibilities, which include parenteral injection, skin applications, or direct mucosal administration by oral, sublingual, or nasal routes. In addition, inclusion of an enterotoxin adjuvant is associated with development of multifaceted cellular and humoral immune responses to vaccination. Here, we review exciting progress in the past few years in clinical trials for safety and efficacy, preclinical vaccines studies, and new mechanistic insights for enterotoxin adjuvants. This includes recent reports of their use in vaccines targeting microbial infections (bacterial, viral, parasitic) or substance abuse drugs.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"85 ","pages":"Article 102398"},"PeriodicalIF":7.0,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0952791523001176/pdfft?md5=bcce107f9388822c7f75015bc5d0223c&pid=1-s2.0-S0952791523001176-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134832548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Animal models of shigellosis: a historical overview 志贺氏菌病的动物模型:历史概述。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-11-10 DOI: 10.1016/j.coi.2023.102399

Noémie Alphonse , Charlotte Odendall

{"title":"Animal models of shigellosis: a historical overview","authors":"Noémie Alphonse , Charlotte Odendall","doi":"10.1016/j.coi.2023.102399","DOIUrl":"10.1016/j.coi.2023.102399","url":null,"abstract":"<div><p><em>Shigella</em> spp. are major causative agents of bacillary dysentery, a severe enteric disease characterized by destruction and inflammation of the colonic epithelium accompanied by acute diarrhea, fever, and abdominal pain. Although antibiotics have traditionally been effective, the prevalence of multidrug-resistant strains is increasing, stressing the urgent need for a vaccine. The human-specific nature of shigellosis and the absence of a dependable animal model have posed significant obstacles in understanding <em>Shigella</em> pathogenesis and the host immune response, both of which are crucial for the development of an effective vaccine. Efforts have been made over time to develop a physiological model that mimics the pathological features of the human disease with limited success until the recent development of genetically modified mouse models. In this review, we provide an overview of <em>Shigella</em> pathogenesis and chronicle the historical development of various shigellosis models, emphasizing their strengths and weaknesses.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"85 ","pages":"Article 102399"},"PeriodicalIF":7.0,"publicationDate":"2023-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0952791523001188/pdfft?md5=15b69b0960d9f25442c6ee7d13dbdea0&pid=1-s2.0-S0952791523001188-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89721289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

AP-1 transcription factors in cytotoxic lymphocyte development and antitumor immunity AP-1转录因子在细胞毒性淋巴细胞发育和抗肿瘤免疫中的作用。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-11-04 DOI: 10.1016/j.coi.2023.102397

Diana Schnoegl , Angela Hiesinger , Nicholas D Huntington , Dagmar Gotthardt

引用次数: 0

The future of vaccination in Latin America: learning from the COVID-19 pandemic 拉丁美洲疫苗接种的未来：从新冠肺炎大流行中学习。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-10-06 DOI: 10.1016/j.coi.2023.102390

Fernando E Díaz, Lourdes Arruvito, Jorge Geffner

引用次数: 0

Human guanylate-binding proteins in intracellular pathogen detection, destruction, and host cell death induction 人鸟苷酸结合蛋白在细胞内病原体检测、破坏和宿主细胞死亡诱导中的作用。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-10-01 DOI: 10.1016/j.coi.2023.102373

Yolanda Rivera-Cuevas, Barbara Clough, Eva-Maria Frickel

引用次数: 0

Nasal vaccines for pertussis 百日咳鼻用疫苗。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-10-01 DOI: 10.1016/j.coi.2023.102355

Pauline Schmitt , Lisa Borkner , Seyed Davoud Jazayeri , Karen N McCarthy , Kingston HG Mills

引用次数: 0

Spatiotemporal and cell-state control of antigen presentation during tolerance and immunity 耐受和免疫过程中抗原呈递的时空和细胞状态控制。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-10-01 DOI: 10.1016/j.coi.2023.102357

Jyh Liang Hor, Ronald N Germain

引用次数: 0

Mitochondrial reactive oxygen species: double agents in Mycobacterium tuberculosis infection 线粒体活性氧：结核分枝杆菌感染的双重因素。

IF 7 2区医学

Current Opinion in Immunology Pub Date : 2023-10-01 DOI: 10.1016/j.coi.2023.102366

Lily M Ellzey , Kristin L Patrick , Robert O Watson

{"title":"Mitochondrial reactive oxygen species: double agents in Mycobacterium tuberculosis infection","authors":"Lily M Ellzey , Kristin L Patrick , Robert O Watson","doi":"10.1016/j.coi.2023.102366","DOIUrl":"10.1016/j.coi.2023.102366","url":null,"abstract":"<div><p><span><span>In addition to housing the major energy-producing pathways in cells, mitochondria are active players in innate immune responses. One critical way mitochondria fulfill this role is by releasing damage-associated molecular patterns (mtDAMPs) that are recognized by innate sensors to activate pathways including, but not limited to, cytokine expression, </span>selective autophagy<span>, and cell death<span>. Mitochondrial reactive oxygen species<span> (mtROS) is a multifunctional mtDAMP linked to pro- and antimicrobial immune outcomes. Formed as a by-product of energy generation, mtROS links mitochondrial metabolism with downstream innate immune responses. As a result, altered cellular metabolism can change mtROS levels and impact downstream antimicrobial responses in a variety of ways. MtROS has emerged as a particularly important mediator of pathogenesis during infection with </span></span></span></span><span><em>Mycobacterium tuberculosis</em></span><span><span> (Mtb), an intracellular bacterial pathogen that continues to pose a significant threat to global </span>public health<span>. Here, we will summarize how Mtb modulates mtROS levels in infected macrophages and how mtROS dictates Mtb infection outcomes by controlling inflammation, lipid peroxidation, and cell death. We propose that mtROS may serve as a biomarker to predict tuberculosis patient outcomes and/or a target for host-directed therapeutics.</span></span></p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"84 ","pages":"Article 102366"},"PeriodicalIF":7.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9769667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0